XTL Biopharmaceuticals (XTLB)
(Delayed Data from NSDQ)
$2.61 USD
0.00 (0.00%)
Updated May 28, 2024 12:51 PM ET
After-Market: $2.55 -0.06 (-2.30%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
XTL Biopharmaceuticals Ltd. [XTLB]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
We are discontinuing coverage due to better allocate resources within our coverage universe
Provider: H.C. Wainwright & Co., Inc.
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for XTLB
Provider: ValuEngine, Inc
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
We are updating coverage on XTL Biopharmaceuticals Ltd
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
Updating coverage on XTL Biopharmaceuticals Ltd. with a fair value bracket of $8.91 (Low-Bracket estimate) and $10.59 (High-Bracket estimate).
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
Phase 2b Study to Initiate in 2016; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
Updating coverage on XTL Biopharmaceuticals Ltd. with a fair value bracket of $9.07
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
Phase 2 Lupus Study On Track for 2016; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
Initiation of Coverage with a fair value bracket of $8.63 (Low-Bracket estimate) and $10.24 (High-Bracket estimate).
Company: XTL Biopharmaceuticals Ltd.
Industry: Medical - Drugs
Taming Lupus Through Tolerance; Initiating with a Buy Rating
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
|